[What newly brought endocrinology by the past 2022?]

Q4 Medicine

Problemy endokrinologii Pub Date : 2023-02-25 DOI:10.14341/probl13261

G A Melnichenko, M V Shestakova

引用次数: 0

Abstract

In the past year, the Federal Project "Fight against Diabetes" 2023-2030 was developed in detail and submitted in detail and submitted to the Government of the Russian Federation, which will significantly improve the practice of working with patients with diabetes, providing them with maximum availability of medical care, including in updated and technologically re -equipped regional endocrinological centers, reviving the active work of "Diabetes schools", "Diabetic foot" rooms, diagnostic laboratories, introducing new forms of communication with patients, including using personal assistants of a doctor, continuous technologies for monitoring glycemia, etc.

查看原文本刊更多论文

[过去的2022年，内分泌学有什么新进展？]

去年，详细制定并向俄罗斯联邦政府提交了 2023-2030 年 "抗击糖尿病 "联邦项目，该项目将显著改善糖尿病患者的工作实践，最大限度地为他们提供医疗服务，包括在更新和技术重新装备的地区内分泌中心，恢复 "糖尿病学校"、"糖尿病足 "室、诊断实验室的积极工作，引入与患者沟通的新形式，包括使用医生个人助理、血糖连续监测技术等。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Problemy endokrinologii Medicine-Endocrinology, Diabetes and Metabolism

CiteScore

1.40

自引率

0.00%

发文量

期刊介绍： Since 1955 the “Problems of Endocrinology” (or “Problemy Endocrinologii”) Journal publishes timely articles, balancing both clinical and experimental research, case reports, reviews and lectures on pressing problems of endocrinology. The Journal is aimed to the most topical issues of endocrinology: to chemical structure, biosynthesis and metabolism of hormones, the mechanism of their action at cellular and molecular level; pathogenesis and to clinic of the endocrine diseases, new methods of their diagnostics and treatment. The Journal: features original national and foreign research articles, reflecting world endocrinology development; issues thematic editions on specific areas; publishes chronicle of major international congress sessions and workshops on endocrinology, as well as state-of-the-art guidelines; is intended for scientists, endocrinologists diabetologists and specialists of allied trade, general practitioners, family physicians and pediatrics.